Dermatology Doctors in Bala Cynwyd, PA Accepting Medicare

6 Dermatology doctors found. Showing 1 - 6

Fatoumata Haidara Camara, PA-C Dermatology Medicare: Accepting Medicare Assignments Practice Location: 50 Monument Rd, Bala Cynwyd, PA 19004 Phone: 610-668-2570

Dr. Mary Elizabeth Griffin, DO Dermatology Medicare: Accepting Medicare Assignments Practice Location: One Bala Plaza, Suite 620, Bala Cynwyd, PA 19004 Phone: 610-664-3300    Fax: 610-664-1151

Lynn Michele Klein, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 50 Monument Rd, Third Floor Suite 301, Bala Cynwyd, PA 19004 Phone: 610-668-2570    Fax: 610-668-2808

Toby Frank Zachian, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: Two Bala Plaza St Il 17, Bala Cynwyd, PA 19004 Phone: 610-667-6277    Fax: 610-667-9755

Dr. Amara Ashjian Lieberman, M.D. Dermatology - Dermatopathology Medicare: Accepting Medicare Assignments Practice Location: 1 Bala Plz, Suite 620, Bala Cynwyd, PA 19004 Phone: 610-664-3300    Fax: 610-664-1151

Dr. Stephen A. Solotoff, M.D. Dermatology Medicare: Medicare Enrolled Practice Location: 191 Presidential Blvd #103, Bala Cynwyd, PA 19004 Phone: 610-667-5003

News Archive

Scientists unravel molecular mechanisms that drive ferroptosis signaling

Ferroptosis is a recently recognized form of regulated necrosis. Up until now, this form of cell death has only been thought to be a possible therapeutic approach to treat tumour cells. Yet, ferroptosis also occurs in non-transformed tissues as demonstrated by this study, thus implicating this cell death pathway in the development of a wide range of pathological conditions. More specifically, the deletion of the ferroptosis-regulating enzyme Gpx4 in a pre-clinical model results in high ferroptosis rates in kidney tubular epithelial cells causing acute renal failure.

Onset Therapeutics expands its sales force to create nationwide presence

Onset Therapeutics LLC, a specialty pharmaceutical company focused in dermatology, today announced that the Company's recent growth and future opportunities have facilitated an expansion of its field sales organization to cover more than twenty-five additional major metropolitan areas.

ACT and Brown Cancer Center scientist collaborate in discovery of new therapeutics for cancer

Advanced Cancer Therapeutics (ACT), a for-profit private company dedicated to bringing new anti-cancer therapies to market, today announced that it has signed an agreement to leverage the computational chemistry expertise of Dr. John Trent, Associate Professor, Department of Medicine at the University of Louisville's James Graham Brown Cancer Center (Brown Cancer Center), to accelerate the identification of new clinical candidates for the prevention and treatment of cancer.

Atox Bio completes AB103 phase 1 study in severe bacterial infections and sepsis

Atox Bio Inc. today announced that it successfully completed a phase 1 clinical study of AB103, a novel therapy for the treatment of severe bacterial infections and sepsis.

Read more Medical News

› Verified 8 days ago